Praxis Precision Medicines Inc (PRAX): Next-Year EPS Estimate 28.25%
As of 2026-06-04, Praxis Precision Medicines Inc (PRAX) has a next-year EPS growth estimate of 28.25%.
On 2026-06-03, analyst consensus for PRAX's next-year EPS growth shifted from 29.89% to 28.25% — a negative change of 1.64 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -12.94%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 28.25%
- EPS growth this year
- -12.94%
- EPS next quarter (est)
- -$3.68
- Last price
- $264.75
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 28.25% | -12.94% | -$3.68 | $264.75 |
| 2026-06-03 | 28.25% | -12.94% | -$3.68 | $278.93 |
| 2026-06-02 | 29.89% | -11.95% | -$3.67 | $258.08 |
| 2026-06-01 | 29.82% | -12.03% | -$3.67 | $335.16 |
| 2026-05-31 | 29.82% | -12.03% | -$3.67 | $349.97 |
| 2026-05-28 | 29.82% | -12.03% | -$3.67 | $352.63 |
| 2026-05-27 | 29.82% | -12.03% | -$3.67 | $357.13 |
| 2026-05-26 | 29.82% | -12.03% | -$3.67 | $350.60 |
| 2026-05-25 | 29.82% | -12.03% | -$3.67 | $343.56 |
| 2026-05-24 | 29.82% | -12.03% | -$3.67 | $343.56 |
| 2026-05-21 | 29.82% | -12.03% | -$3.67 | $350.56 |
| 2026-05-20 | 29.82% | -12.03% | -$3.67 | $335.61 |
| 2026-05-19 | 29.82% | -12.03% | -$3.67 | $320.61 |
| 2026-05-18 | 29.82% | -12.03% | -$3.67 | $320.53 |
| 2026-05-17 | 29.82% | -12.03% | -$3.67 | $342.58 |
| 2026-05-14 | 29.82% | -12.03% | -$3.67 | $345.52 |
| 2026-05-13 | 29.82% | -12.03% | -$3.67 | $339.90 |
| 2026-05-12 | 35.07% | -11.95% | -$3.71 | $343.20 |
| 2026-05-11 | 34.91% | -12.31% | -$3.72 | $331.81 |
| 2026-05-10 | 34.91% | -12.31% | -$3.72 | $330.02 |
| 2026-05-07 | 35.82% | -12.31% | -$3.73 | $333.28 |
| 2026-05-06 | 36.76% | -11.20% | -$3.57 | $338.07 |
| 2026-05-05 | 36.76% | -11.20% | -$3.57 | $333.30 |
| 2026-05-04 | 36.76% | -11.20% | -$3.57 | $337.61 |
| 2026-05-03 | 36.76% | -11.20% | -$3.57 | $324.20 |
| 2026-04-30 | 36.76% | -11.20% | -$3.57 | $318.83 |
| 2026-04-29 | 36.76% | -11.20% | -$3.57 | $323.19 |
| 2026-04-28 | 36.76% | -11.20% | -$3.57 | $321.92 |
| 2026-04-27 | 36.76% | -11.20% | -$3.57 | $330.99 |
| 2026-04-26 | 36.76% | -11.20% | -$3.57 | $344.82 |
Recent News
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- The Shocking Twist That Sent This Seizure-Focused Biotech Into A DiveInvestor's Business Daily
- PRAX Stock Drops 12% After Hours On Trial Setback Retail Eyes FDA Approval Of Other Pipeline CandidatesStocktwits
- Praxis Precision Medicines Provides Vormatrigine Program UpdateGlobeNewswire
- Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish BreakoutInvestor's Business Daily
- Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential TremorGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Praxis Precision Medicines Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Praxis Precision Medicines Inc (PRAX) has a next-year EPS growth estimate of 28.25%, based on analyst consensus.
When was the latest EPS estimate revision for PRAX?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 29.89% to 28.25%.
What sector and industry does Praxis Precision Medicines Inc belong to?▾
Praxis Precision Medicines Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. PRAX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Praxis Precision Medicines Inc (PRAX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports